financetom
Business
financetom
/
Business
/
Sonos Insider Sold Shares Worth $429,375, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sonos Insider Sold Shares Worth $429,375, According to a Recent SEC Filing
Aug 22, 2024 2:06 AM

04:22 PM EDT, 08/21/2024 (MT Newswires) -- Maxime Bouvat-Merlin, Chief Product Officer, on August 19, 2024, sold 37,256 shares in Sonos ( SONO ) for $429,375.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1314727/000112760224022707/xslF345X05/form4.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Soccer-Man Utd humbled as Diaz double helps Liverpool humiliate rivals
Soccer-Man Utd humbled as Diaz double helps Liverpool humiliate rivals
Sep 1, 2024
MANCHESTER, England, Sept 1 (Reuters) - Two goals from Luis Diaz and one from Mohamed Salah helped Liverpool stroll to a 3-0 victory at Manchester United ( MANU ) in the Premier League on Sunday, with Erik ten Hag's side humbled by their fierce rivals. Liverpool dominated a United team who could not keep pace with them in the first...
Lexaria Bioscience Says Its Second Weight Loss Drug Human Study Showed No Adverse Events
Lexaria Bioscience Says Its Second Weight Loss Drug Human Study Showed No Adverse Events
Sep 1, 2024
09:10 AM EDT, 08/30/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Friday that its DehydraTECH-processed Rybelsus weight loss capsules showed more tolerability in delivering the GLP-1 drug semaglutide than commercially available Rybelsus in their second human pilot study. The study revealed that none of the nine participants who took the DehydraTECH-processed Rybelsus capsules experienced any adverse events, whereas...
BridgeBio Pharma Reports Positive Additional Data From Phase 3 Study of Acoramidis; Shares Rise
BridgeBio Pharma Reports Positive Additional Data From Phase 3 Study of Acoramidis; Shares Rise
Sep 1, 2024
12:02 PM EDT, 08/30/2024 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said Friday that additional data from a phase 3 study of acoramidis in transthyretin amyloid cardiomyopathy or ATTR-CM showed that switching from standard of care treatment and placebo to acoramidis increased serum transthyretin at the first month. The increase in serum transthyretin or TTR was correlated with reduced...
China to pitch green tech exports to African leaders as Western curbs loom
China to pitch green tech exports to African leaders as Western curbs loom
Sep 1, 2024
BEIJING/NAIROBI (Reuters) - China will urge a summit of 50 African nations in Beijing this week to take more of its goods, before Western curbs kick in on its exports such as electric vehicles and solar panels, in exchange for more pledges of loans and investment. But the dozens of African leaders arriving in the Chinese capital for the three-yearly...
Copyright 2023-2026 - www.financetom.com All Rights Reserved